APVO

Business Context and Reporting Period

Aptevo Therapeutics Inc. (APVO) is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer treatment using its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies. The company reported for the fiscal year ended December 31, 2024. As of the filing date, Aptevo has two clinical candidates (mipletamig and ALG.APV-527) and three preclinical candidates in development. The company is listed on the Nasdaq Capital Market.

Key Financial Metrics

Revenue: The company generated no product revenue in 2024. Revenue from discontinued operations was $0 in 2024 compared to $1.2 million in 2023.

Debt: The company had no long-term debt outstanding as of December 31, 2024. A MidCap term loan was fully repaid in Q1 2023.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $6.7 million year-over-year, primarily due to the absence of a $9.7 million gain from the sale of non-financial assets (XOMA transaction) recorded in 2023 and the absence of $1.2 million in income from discontinued operations.
• Expense Reductions: R&D expenses decreased by $2.7 million, driven by lower preclinical spending and the conclusion of the Phase 1b dose expansion study for mipletamig. G&A expenses decreased by $1.6 million due to lower employee and consulting costs.
• Capital Raises: The company raised significant capital in 2024 through multiple registered direct offerings and warrant inducement agreements, resulting in $15.6 million in net financing cash flows compared to $6.0 million in 2023.
• Stock Splits: The company executed two reverse stock splits in 2024 (1-for-44 in March and 1-for-37 in December) to regain compliance with Nasdaq listing requirements.

Guidance, Outlook, and Risks

Clinical Progress:

• Mipletamig (AML): The RAINIER Phase 1b/2 trial in frontline AML patients showed 100% remission in Cohort 1 within 30 days. Cohort 2 is currently enrolling.
• ALG.APV-527 (Solid Tumors): Interim data from the Phase 1 dose escalation study showed 59% of evaluable patients achieved stable disease, with no severe liver toxicity observed.

Liquidity and Going Concern:

• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year from the date of issuance of the financial statements.
• With $8.7 million in cash, the company requires additional funding to complete clinical development. Plans include raising capital through equity financings, warrant exercises (potential $16.5 million gross proceeds), or strategic partnerships.

Key Risks:

• Capital Constraints: Inability to raise additional capital on acceptable terms could force the company to delay or terminate clinical trials.
• Delisting Risk: While the company regained compliance with Nasdaq bid price requirements in December 2024, future failure to maintain listing standards could adversely affect liquidity.
• Regulatory and Clinical Uncertainty: Results from early-stage trials may not predict future success, and regulatory approval is not guaranteed.

Investor Verification Checklist

• Going Concern Status: Verify the company's specific timeline and strategy for securing the additional capital required to fund operations beyond the next 12 months.
• Warrant Exercise Potential: Review the terms of the 1.67 million outstanding warrants and the likelihood of the $16.5 million in potential proceeds being realized.
• Clinical Trial Enrollment: Monitor enrollment rates and safety data for the RAINIER (mipletamig) and ALG.APV-527 trials, as these are critical for future valuation.
• Reverse Stock Split Impact: Assess the impact of the recent 1-for-37 reverse stock split on share liquidity and market perception.
• IXINITY Milestones: Confirm the status of potential milestone payments from Medexus regarding the IXINITY business, which was sold in 2020 (with a portion of rights sold to XOMA in 2023).